--- title: "Verrica Pharmaceuticals | 8-K: FY2026 Q2 Revenue Beats Estimate at USD 5.862 M" type: "News" locale: "en" url: "https://longbridge.com/en/news/295152864.md" datetime: "2026-08-06T22:32:21.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/295152864.md) - [en](https://longbridge.com/en/news/295152864.md) - [zh-HK](https://longbridge.com/zh-HK/news/295152864.md) generator: "portal-rs" --- # Verrica Pharmaceuticals | 8-K: FY2026 Q2 Revenue Beats Estimate at USD 5.862 M Revenue: As of FY2026 Q2, the actual value is USD 5.862 M, beating the estimate of USD 5.737 M. EPS: As of FY2026 Q2, the actual value is USD -0.62, missing the estimate of USD -0.41. EBIT: As of FY2026 Q2, the actual value is USD -13.04 M. ### Second Quarter 2026 Financial Results #### Revenue - Total revenue for the three months ended June 30, 2026, was $5.9 million, compared to $12.7 million for the same period in 2025. - U.S. YCANTH product revenue, net, was $5.1 million for the quarter ended June 30, 2026, an increase from $4.5 million in the prior year. - License and collaboration revenue was $0.8 million for the second quarter of 2026, a decrease from $8.2 million in the second quarter of 2025. #### Operating Expenses - Costs of product revenue were $0.4 million for the second quarter of 2026, up from $0.3 million in the second quarter of 2025. - Cost of collaboration revenue was $0.443 million for the second quarter of 2026, compared to $0.154 million for the same period in 2025. - Selling, general and administrative expenses increased to $10.3 million in Q2 2026 from $8.9 million in Q2 2025. - Research and development expenses rose to $6.0 million in Q2 2026 from $1.8 million in Q2 2025. - An expense of $1.7 million was recognized in Q2 2026 for a legal settlement, net of insurance recovery. - Total expenses were $19.0 million for the three months ended June 30, 2026, compared to $11.2 million for the same period in 2025. #### Profitability - Loss from operations was - $13.1 million for Q2 2026, compared to income from operations of $1.5 million for Q2 2025. - Net loss was - $13.2 million for Q2 2026, compared to a net income of $0.2 million for Q2 2025. - Non-GAAP net loss was - $10.2 million for Q2 2026, versus a non-GAAP net income of $1.2 million for Q2 2025. #### Other Financial Items - Interest income decreased to $0.1 million in Q2 2026 from $0.2 million in Q2 2025. - Interest expense decreased to - $0.2 million in Q2 2026 from - $2.1 million in Q2 2025. - Change in fair value of derivative liability was $0 in Q2 2026, compared to $0.6 million in Q2 2025. ### Year-to-Date Financial Results (Six Months Ended June 30, 2026) #### Revenue - Product revenue, net, was $9.4 million for the six months ended June 30, 2026, up from $8.0 million for the same period in 2025. - License and collaboration revenue was $1.5 million for the six months ended June 30, 2026, a decrease from $8.2 million for the same period in 2025. - Total revenue was $10.9 million for the six months ended June 30, 2026, compared to $16.1 million for the same period in 2025. #### Operating Expenses - Costs of product revenue were $1.0 million for the six months ended June 30, 2026, up from $0.8 million in the prior year period. - Cost of collaboration revenue was $0.8 million for the six months ended June 30, 2026, compared to $0.2 million for the same period in 2025. - Selling, general and administrative expenses were $20.3 million for the six months ended June 30, 2026, compared to $17.7 million for the same period in 2025. - Research and development expenses were $9.9 million for the six months ended June 30, 2026, up from $4.1 million for the same period in 2025. - An expense of $1.7 million was recognized for a legal settlement, net of insurance recovery, during the six months ended June 30, 2026. - Total expenses were $33.7 million for the six months ended June 30, 2026, compared to $22.8 million for the same period in 2025. #### Profitability - Loss from operations was - $22.8 million for the six months ended June 30, 2026, compared to - $6.6 million for the same period in 2025. - Net loss was - $22.8 million for the six months ended June 30, 2026, compared to a net loss of - $9.5 million for the same period in 2025. - Non-GAAP net loss was - $19.0 million for the six months ended June 30, 2026, compared to a non-GAAP net loss of - $7.1 million for the same period in 2025. #### Other Financial Items - Interest income was $0.3 million for the six months ended June 30, 2026, down from $0.6 million in the prior year. - Interest expense was - $0.3 million for the six months ended June 30, 2026, a decrease from - $4.3 million for the same period in 2025. - Change in fair value of derivative liability was $0 for the six months ended June 30, 2026, compared to $0.9 million for the same period in 2025. ### Balance Sheet Data (as of June 30, 2026) #### Assets - Cash was $11.2 million as of June 30, 2026, down from $30.1 million as of December 31, 2025. - Accounts receivable increased to $11.1 million as of June 30, 2026, from $5.4 million as of December 31, 2025. - Total current assets were $32.6 million as of June 30, 2026, compared to $42.5 million as of December 31, 2025. - Total assets were $36.0 million as of June 30, 2026, compared to $47.1 million as of December 31, 2025. #### Liabilities and Stockholders’ Equity - Legal settlement liability was $4.0 million as of June 30, 2026. - R&D funding liability was $8.4 million as of June 30, 2026, up from $5.1 million as of December 31, 2025. - Total liabilities were $31.7 million as of June 30, 2026, compared to $22.4 million as of December 31, 2025. - Total stockholders’ equity was $4.3 million as of June 30, 2026, down from $24.7 million as of December 31, 2025. ### Operational Metrics - YCANTH dispensed applicator units reached 19,626 in Q2 2026, representing a 28.3% increase over the previous quarter and a 46.1% year-over-year increase. ### Outlook / Guidance Verrica Pharmaceuticals Inc. expects to present topline data from its global Phase 3 program for common warts in mid-2027. The company’s cash runway could extend into 2028, based on its current operating plan and the full availability of its new $27.5 million credit facility. This credit facility provides additional non-dilutive capital to support YCANTH commercialization and advance the common warts program. ### Related Stocks - [VRCA.US](https://longbridge.com/en/quote/VRCA.US.md) ## Related News & Research - [Verrica completes enrollment in Phase 3 COVE-2 trial of YCANTH for common warts, sees data in Q1 2027](https://longbridge.com/en/news/297181851.md) - [Verrica Interim CFO John J. Kirby acquires $24,650 of common shares](https://longbridge.com/en/news/296270069.md) - [Verrica Pharmaceuticals closes credit facility for up to $27.5 million with entity controlled by Chairman Paul Manning](https://longbridge.com/en/news/295136525.md) - [Verrica signs exclusive deal with Medomie to market Ycanth in Israel](https://longbridge.com/en/news/293338821.md) - [H.C. Wainwright Sticks to Their Buy Rating for Verrica Pharmaceuticals (VRCA)](https://longbridge.com/en/news/290450387.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**